GlassScriptPhysician profile
Gwendolyn Yn Knuckles
NPI 1043253677
$9,095.46
in general payments reported to CMS, 2019-2025
49 companies · $571 in 2025
The $571 reported for 2025 was more than what 78% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,193 · 2020: $982 · 2021: $1,521 · 2022: $3,229 · 2023: $759 · 2024: $840 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,170.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,690.28 | 2019-2025 | |
| Applied Medical Resources Corporation | $1,646.29 | 2022 | |
| Novo Nordisk INC | $1,305.94 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lupin INC. | $846.59 | 2019-2021 | |
| Lilly USA, LLC | $396.69 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $355.28 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $339.33 | 2019-2022 | |
| Pfizer INC. | $336.50 | 2019-2025 | |
| Axsome Therapeutics, INC. | $282.06 | 2023-2025 | Auvelity |
| Astellas Pharma US INC | $226.00 | 2020-2025 | Veozah |
| Myovant Sciences INC. | $159.88 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $150.41 | 2019-2025 | Airsupra |
| Zyla Life Sciences, INC. | $148.75 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $121.46 | 2019-2024 | Contrave |
| Sumitomo Pharma America, INC. | $103.28 | 2023-2025 | Myfembree |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gwendolyn Knuckles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.